Bicara Therapeutics (NASDAQ:BCAX) Receives “Market Outperform” Rating from Citizens Jmp

Citizens Jmp reiterated their market outperform rating on shares of Bicara Therapeutics (NASDAQ:BCAX) in a research note issued to investors on Tuesday,Benzinga reports. They currently have a $31.00 price objective on the stock.

BCAX has been the subject of several other research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Bicara Therapeutics in a research note on Friday, January 9th. Citigroup initiated coverage on Bicara Therapeutics in a research report on Thursday, January 29th. They set an “outperform” rating on the stock. BTIG Research reissued a “buy” rating on shares of Bicara Therapeutics in a report on Thursday, January 15th. Mizuho upgraded Bicara Therapeutics to a “hold” rating in a research report on Thursday, December 18th. Finally, UBS Group reaffirmed a “buy” rating on shares of Bicara Therapeutics in a research note on Wednesday, January 14th. Eight analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $28.00.

Bicara Therapeutics Price Performance

Shares of NASDAQ:BCAX opened at $19.89 on Tuesday. The company’s fifty day moving average price is $17.21 and its 200-day moving average price is $16.67. The firm has a market capitalization of $1.09 billion, a price-to-earnings ratio of -7.86 and a beta of -0.78. Bicara Therapeutics has a one year low of $7.80 and a one year high of $20.25.

Bicara Therapeutics (NASDAQ:BCAX) last posted its quarterly earnings data on Monday, March 30th. The company reported ($0.68) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.04. As a group, equities research analysts expect that Bicara Therapeutics will post -2.59 EPS for the current year.

Insider Buying and Selling at Bicara Therapeutics

In other Bicara Therapeutics news, insider David Raben sold 16,300 shares of the company’s stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $18.52, for a total transaction of $301,876.00. Following the completion of the sale, the insider directly owned 55,286 shares in the company, valued at $1,023,896.72. This represents a 22.77% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Claire Mazumdar sold 1,596 shares of the firm’s stock in a transaction dated Friday, March 20th. The shares were sold at an average price of $18.95, for a total value of $30,244.20. Following the transaction, the chief executive officer directly owned 339,392 shares in the company, valued at $6,431,478.40. This trade represents a 0.47% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 137,969 shares of company stock valued at $2,586,198.

Hedge Funds Weigh In On Bicara Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Mirae Asset Global Investments Co. Ltd. purchased a new position in Bicara Therapeutics in the 4th quarter worth approximately $45,000. Legal & General Group Plc boosted its stake in shares of Bicara Therapeutics by 64.1% during the second quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock valued at $29,000 after purchasing an additional 1,233 shares during the period. Ameritas Investment Partners Inc. grew its holdings in shares of Bicara Therapeutics by 73.0% in the second quarter. Ameritas Investment Partners Inc. now owns 3,493 shares of the company’s stock worth $32,000 after purchasing an additional 1,474 shares during the last quarter. Larson Financial Group LLC grew its holdings in shares of Bicara Therapeutics by 1,015.5% in the third quarter. Larson Financial Group LLC now owns 3,949 shares of the company’s stock worth $62,000 after purchasing an additional 3,595 shares during the last quarter. Finally, Tower Research Capital LLC TRC increased its stake in shares of Bicara Therapeutics by 419.3% in the second quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company’s stock worth $44,000 after buying an additional 3,866 shares during the period.

More Bicara Therapeutics News

Here are the key news stories impacting Bicara Therapeutics this week:

• Positive Sentiment: Phase‑3 advancement and clinical catalysts: Bicara selected a 1,500 mg weekly dose of ficerafusp alfa and has initiated the pivotal FORTIFI‑HN01 trial with interim Phase‑3 readout expected mid‑2027; long‑term Phase‑1b follow‑up is slated for ASCO 2026 — these program milestones underpin upside potential. Article Title
• Positive Sentiment: Corporate update & financials: Q4/FY‑2025 release highlighted a strong cash position, selection of the Phase‑3 dose, and a less‑frequent dosing regimen in development — gives runway to reach clinical milestones. Article Title
• Positive Sentiment: Strong buy-side analyst support from some firms: HC Wainwright reiterated a Buy and boosted its PT to $42; Citizens Jmp and Wedbush reaffirmed market/outperform views with $31 and $30 targets — these bulls can attract momentum buyers. Article Title
• Neutral Sentiment: Modest Q4 beat: Bicara reported EPS of ($0.68) vs. consensus ($0.72) — a small beat but still operating at losses as expected for a clinical‑stage biotech. Press Release
• Neutral Sentiment: Mixed mid‑range analyst moves: Goldman Sachs and Wells Fargo raised price targets to $16 but kept Neutral/Equal‑Weight ratings (their PTs sit below the current trading level), which tempers upside for cautious investors. Article Title
• Negative Sentiment: Insider sale: CEO Claire Mazumdar sold ~8,234 shares (~$154k) in early March, trimming her direct holdings — a small insider sale but some investors view insider selling as a cautionary signal. Article Title

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.